Form 4: Corcept Therapeutics Executive Gary Robb Reports Stock Transactions

Gary Robb, Chief Business Officer at Corcept Therapeutics, reported the acquisition and disposal of company stock, including shares withheld for tax obligations and new shares purchased under a company plan.

Summary

• Gary Robb, Chief Business Officer of Corcept Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of company stock.
• On December 2, 2024, 324 shares were withheld to cover tax obligations related to vesting restricted stock units at a price of $57.68 per share.
• On the same day, Mr. Robb acquired 290 shares through a company purchase plan at $59.21 per share.
• Additionally, 290 shares were granted as unvested restricted stock awards under the same purchase plan.
• Mr. Robb's total direct holdings increased to 20,119 shares, which includes unvested restricted stock awards.
• He also has indirect ownership of 9,665 shares held in a custodial account for his child.

Sentiment

Score: 7

Explanation: The document reflects routine transactions by an executive, which is generally neutral to positive. The purchase of shares indicates confidence, but the withholding for taxes is a standard procedure.

Positives

• The purchase of shares by the Chief Business Officer demonstrates confidence in the company's future.
• The vesting of restricted stock units indicates the executive is meeting performance requirements.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the ownership changes of key personnel.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The transactions reported are typical for executives who receive stock-based compensation and participate in company purchase plans.
• Similar filings can be seen from executives at comparable pharmaceutical companies such as AbbVie, Eli Lilly, and Regeneron.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment due to the executive's purchase of shares.
• The vesting of restricted stock units is a standard part of executive compensation and has no significant impact on other stakeholders.

Key Dates

Keywords

Form 4, Corcept Therapeutics, Stock Transactions, Beneficial Ownership, Gary Robb, Restricted Stock Units, Insider Trading